20 Mar 2020

Lonza Joins the MIT Industrial Liaison Program

Downloads

  • Lonza joins the MIT Industrial Liaison Program (ILP), gaining access to a vibrant ecosystem of research and technology development.
  • Lonza’s membership in MIT’s ILP aims to open new possibilities for research collaborations relevant to drug product development, manufacturing and delivery.
  • This agreement strengthens Lonza’s commitment to anticipating and meeting the needs of biotech and pharmaceutical companies developing innovative medicines.  

Quote from Hanns-Christian Mahler, Head Drug Product Services at Lonza:

“MIT’s world-leading capacity to overcome technological challenges perfectly match with Lonza’s entrepreneurial spirit and drive to develop flexible solutions that fulfill patients’ needs. By joining the MIT Industrial Liason Program we hope to engage in future research opportunties that will further accelerate Lonza Pharma & Biotech’s mission to deliver the medicines of tomorrow, today.”

Basel, Switzerland, 20 March 2020 – Lonza announced today that it has joined the Massachusetts Institute of Technology's (MIT's) Industrial Liaison Program (ILP) - a program dedicated to establishing technology transfer and research collaboration between industry and academia for societal benefit. As the pace of technological advances accelerates, the ILP is committed to translating fundamental discoveries into productive, applied interaction with industry.

The agreement aims to develop a mutually beneficial relationship between MIT and Lonza, bringing new opportunities for dialogue between research scientists and faculty members as well as student exchanges and sharing management practices. Lonza will count on the multidisciplinary expertise of over 300 research centers and institutes, more than 3000 researchers, and the possibility to connect with over 1700 technology-based startups connected to MIT.

Lonza is committed to delivering increasingly complex medicines to market in record time and to anticipate the requirements for scaling emerging modalities, ensuring innovation in medicines reaches patients.